Truist lowered the firm’s price target on Allogene Therapeutics (ALLO) to $18 from $20 and keeps a Buy rating on the shares. Caribou Biosciences (CRBU) will likely beat its “potent competitor” to ALLO-501A in LBCL, or large B cell lymphoma, the analyst tells investors in a research note. The firm adds that while it remains confident that Allogene will be the first among allogeneic CAR-Ts to make it to the market in LBCL, it also sees CB-010 competing with ALLO in the earlier line setting.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALLO:
- Allogene Therapeutics assumed with an Outperform at Oppenheimer
- Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
- Allogene Therapeutics provides additional ALLO-501/501A Phase 1 data
- Allogene Therapeutics Announces Departure of Chief Financial Officer
- Allogene Therapeutics CFO Eric Shcmidt to step down
